Petruo, Vanessa
Bodmer, Benjamin
Bluschke, Annet
Münchau, Alexander
Roessner, Veit
Beste, Christian
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (FOR 2698, BE4045/19-1, FOR 2698)
Article History
Received: 12 June 2019
Accepted: 10 January 2020
First Online: 24 January 2020
Competing interests
: V.P., B.B. and A.B. have nothing to disclose. V.R. has received payment for consulting and writing activities from Lilly, Novartis, and Shire Pharmaceuticals, lecture honoraria from Lilly, Novartis, Shire Pharmaceuticals, and Medice Pharma, and support for research from Shire and Novartis. He has carried out (and is currently carrying out) clinical trials in cooperation with the Novartis, Shire, and Otsuka companies. A.M. has received commercial research support and honoraria from Pharm Allergan, Ipsen, Merz Pharmaceuticals, Actelion, GlaxoSmithKline, Desitin and Teva. C.B. has received payment for consulting from Bayer, GlaxoSmithKline, Novartis, Teva and Genzyme.